The company will collaborate the Parker Institute for Cancer Immunotherapy, Institut Gustave Roussy in France, and the University Health Network in Toronto, Canada.
A NorthShore University HealthSystem and Color pilot picked up pathogenic variants in nearly 9 percent of unselected individuals with a hereditary cancer gene test.
